Jack, I missed this from the XOMA site. Late Sept meeting ICAAC in San Diego.
September '98
International Endotoxin Society Meeting
12, Santa Fe, NM
Pat Scannon, M.D., Ph.D., rBPI-21 Clinical Update
38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC
'98), ASM's Annual Meeting on Infectious Diseases
24-27, San Diego, CA
Steve Carroll, Ph.D., "Plasma Levels of Lipopolysaccharide Binding Protein
(LBP) Indicate That Hemorrhagic Trauma Patients, Partial Hepatectomy Patients and
Cystic Fibrosis Patients Have Been Systemically Exposed to Bacteria and Endotoxin"
Peter Heseltine, M.D., "Open-label, Pilot Phase II Trial of Three Dose Levels
of Recombinant Bactericidal/ Permeability- Increasing Protein (rBPI-21) Administered
by Continuous Intravenous Infusion to Patients with Complicated Intra-Abdominal
Infections"
Arnold Horwitz, Ph.D., "rBPI(10-193) is Secreted by CHO Cells and Retains
the Activity of rBPI-21"
Lewis Lambert, M.S., "Recombinant Bactericidal/ Permeability- Increasing
Protein in Combination with Sulfadiazine is Remarkably Active Against Toxoplasma
gondii"
Roger Little, Ph.D., "XMP Antifungal Peptides Demonstrate Enhanced
Selectivity and Oral Availability"
|
